Scans global pipelines and surfaces the best licensing or acquisition targets. It compares deal terms, valuations, and competitive pressure to support the Human CBO in decision making on assets.

Evaluates the scientific basis and translational potential of each asset. It reviews data quality, biological plausibility, and experimental gaps to support the Human CSO in scientific decision making.

Analyzes data packages against FDA, EMA, and NMPA expectations. It highlights gaps, reviewer concerns, and pathway options to support the Human Regulatory Lead in regulatory decision making.

Reviews clinical rationale, patient segmentation, biomarkers, and indication strategy. It compares endpoints, protocol options, and operational risks to support the Human Clinical–Medical Lead in shaping and executing the strongest development plan.

Evaluates manufacturing readiness, process robustness, and analytical controls. It compares suppliers, scalability options, and CMC risks to support the Human CMC Lead in ensuring reliable and compliant production.

Assesses patent strength, freedom-to-operate, and global IP exposure. It reviews prior art, claim scope, and deal terms to support the Human IP Lawyer in securing and protecting the asset.

Reviews cross-border deal structures, liability exposure, and contractual protections. It compares terms, obligations, and risk scenarios to support the Human Deal Lawyer in negotiating and safeguarding each agreement.

Models burn, milestones, and funding requirements across programs. It compares financial scenarios, payment structures, and compliance needs to support the Human CFO in maintaining financial strength and readiness.

Analyzes portfolio strategy, clinical risk, and capital needs across all programs. It compares asset value paths, development timelines, and partnership leverage to support the Human CEO in steering the company toward the highest scientific and financial return.